Background--The relationship between lowering LDL (low-density lipoprotein) cholesterol with contemporary lipid-lowering therapies and incident diabetes mellitus (DM) remains uncertain.
L DL (low-density lipoprotein) cholesterol (LDL-C) is a wellestablished modifiable risk factor for clinical atherosclerotic cardiovascular disease. 1, 2 Incremental reductions in LDL-C levels by statins or intensifying statin therapy by adding ezetimibe or PCSK9 (proprotein convertase subtilisin/ kexin type 9) have shown correspondingly higher cardiovascular risk reductions. [3] [4] [5] [6] In contrast, several studies have shown a significant association between statins and a higher risk of incident diabetes mellitus (DM). 7, 8 However, this association is not clear in case of PCSK9 inhibitors. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial showed nonsignificantly higher numbers of incident DM among participants receiving evolocumab. 9 Conversely, the ODYS-SEY OUTCOMES (Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome) trial showed lesser risk of
Study Selection
The following prespecified inclusion criteria were used. First, randomized controlled trials had to include at least 100 patients receiving the allocated pharmacological lipid-lowering therapy for a minimum of 12 weeks. Second, consistent with former reports, 1,2,6 we selected statin and nonstatin therapies in combination with statin that lower LDL-C levels via mechanisms that ultimately result in upregulation of LDL receptor (R) expression (ezetimibe and PCSK9 inhibitors [alirocumab and evolocumab]) compared with placebo or active controls. Third, studies had to report at least 1 clinical event for incident DM. We excluded trials if (1) nonstatin therapy did not reduce LDL-C levels primarily via upregulation of LDLR expression (fibrates, niacin, and cholesteryl ester transfer protein inhibitors), (2) interventions showed concomitant effect on DM (bile acid sequestrants, ileal bypass surgery, exercise, and diet), [14] [15] [16] (3) findings of the study were reported as abstracts and do not have subsequent full-text publication (risk of having discrepancies between meeting abstract results and full-text publication), 17, 18 and (4) trials assessing efficacy of bococizumab, which is not a therapeutic option because of immunogenicity. 19 
Clinical Perspective
What Is New?
• Statins and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce cardiovascular risk by reducing LDL (low-density lipoprotein) cholesterol.
• Statins are known to increase the risk of incident diabetes mellitus (DM), whereas randomized controlled trials have shown numerically higher cases of incident DM with PCSK9 inhibitor therapy.
• It is not clearly known whether LDL cholesterol reduction is associated with risk of incident DM and whether this risk might vary across established LDL cholesterol-lowering drugs.
What Are the Clinical Implications?
• This meta-analysis shows that among intensive lipidlowering drugs, there was no independent association between LDL cholesterol reduction achieved by these medications and risk of incident DM.
• The increased risk of incident DM was associated with statins only; PCSK9 inhibitors did not show any association with DM.
• The current study further adds to the safety of LDL cholesterol lowering with regard to the risk of DM.
Data Extraction and Quality Assessment
Data extraction was performed by 2 independent authors (S.U.K. and H.R.) on a standard data collection form. The data abstraction was based on baseline characteristics of participants, treatment groups, events, total number of patients in each group, diabetic patients in each group, nondiabetic patients in each group (calculated as total patients minus diabetic patients), baseline LDL-C and reduction in LDL-C in each group, achieved LDL-C in each group and difference between the groups, and follow-up duration of each trial. We extracted data on incident DM using the methodology reported in a former study, namely, if the trial had clearly reported newly diagnosed DM as an adverse event or study participants had commenced antidiabetic drug treatment during the trial or if patients had 2 consecutive fasting blood glucose levels ≥126 mg/dL during the study period. 7 The absolute change in LDL-C was calculated as mean or median difference, whichever was available, averaged over the course of follow-up between 2 groups. If not reported, then the achieved LDL-C value at the point closest to 50% of the median follow-up was used. 1 To assess the precision of calculated LDL-C values, we compared our results with the Cholesterol Treatment Trialists (CTT) collaboration meta-analysis 20 and a metaanalysis by Silverman et al. 1 In older studies, for which LDL-C was not available, we calculated the LDL-C from total cholesterol using the following regression equation: LDL-C= (total cholesterol)9[(total cholesterol)90.0012+0.3793].
1
When available, we extracted data for intention to treat analysis. Any discrepancy related to data was resolved by discussion and referring to the original article. We also reviewed prior systematic reviews and meta-analyses for any additional information on the included studies in case the authors had reported further data beyond published trials in those meta-analyses. 1, 7, 8 The Cochrane Collaboration tool for bias risk assessment was used by 2 independent reviewers (V.O. and M.S.K.) to assess the quality of each trial (Table S2) . 21 More intensive lipid-lowering therapy was defined as a more potent pharmacological strategy, whereas less intensive lipidlowering therapy corresponded to placebo/usual care or the active control group of the trial. 2, 6 The group allocation was designated as such: (1) for statin versus placebo/usual care trials, statin therapy belonged to the more intensive therapy group and placebo/usual care was allocated to the less intensive therapy arm; (2) for higher intensive versus lower intensity statin trials, higher intensity statin was grouped with more intensive lipid-lowering therapy and less intensive statin was grouped with less intensive lipid-lowering therapy; and (3) for PCSK9 inhibitor trials, PCSK9 inhibitor therapy was grouped with more intensive lipid-lowering therapy and placebo/usual care or active control (ezetimibe) was grouped with less intensive lipid-lowering therapy.
Data Synthesis and Analysis
To account for potential between-study variance, estimates were pooled using a DerSimonian and Laird random-effects model. 22 The principal summary statistic was risk ratio (RR), supplemented by risk difference (RD) with 95% CI. Heterogeneity was assessed using Cochrane Q statistics and quantified by I 2 with values >25%, 50%, and 75% consistent with low, moderate, and high degrees of heterogeneity, respectively.
23
Publication bias was assessed using the funnel plot and Egger regression test. 24 Statistical significance was set at 5%.
Metaregression analyses were performed using randomeffects models with the restricted maximum likelihood estimation. The Knapp and Hartung adjustment was applied for calculation of standard errors of the estimated coefficients to calculate summary effect estimates. 25 Metaregression analyses were conducted to estimate the associations among absolute amount of reduction in LDL-C (calculated as the difference in the achieved LDL-C between the 2 interventions), 1 percentage reduction in LDL-C (each 10%), baseline LDL-C, and absolute reduction in LDL-C adjusted for baseline LDL-C and incident DM. The index R 2 value (defined as the ratio of explained/total variance) was used to determine the proportion of variance accounted for by the change in LDL-C. Subgroup analyses were conducted according to weighted between-group LDL-C differences observed at follow-up across the trials for particular lipid-lowering strategies as suggested by CTT collaboration meta-analysis 20 Table 1 . Figure 4 ). Meta-analysis of the entire population showed that 6.1% (5121/83 123) of patients had incident DM with the more intensive lipid-lowering therapy versus 5.8% (4734/80 565) with the less intensive lipid-lowering therapy. More intensive lipid-lowering therapy was associated with a higher risk of incident DM compared with less intensive therapy (RR: 1.07; 95% CI, 1.03-1.11; P<0.001; I 2 =0%; RD: 0.003; 95% CI, 0.001-0.006; P=0.002; I 2 =23%; Figure 5 ). These results were Figure 6 ). Sensitivity analysis for trials with ≥500 patients and follow-up ≥1 year showed consistent results (P=0.03 for interaction; Figure 7 ). Meta-analysis according to the fixed-effects model (Table S4) or sensitivity analyses according to year of publication and definition of DM showed consistent results (Table S5 ). The Egger regression test did not detect publication bias ( Figure S1 ).
Discussion
In this meta-analysis we report that over a mean follow-up duration of 4 years, metaregression analysis did not show significant association between reduction in LDL-C by more intensive lipid-lowering therapy and risk of incident DM. The 7% RR and 0.3% absolute risk of incident DM across more intensive lipid-lowering strategy was driven by 10% higher RR and 0.4% absolute risk with statins. Conversely, PCSK9 inhibitors in the setting of background statin therapy were not associated with significant risk of incident DM. These results suggest that among the intensive lipid-lowering strategies, the modest risk of incident DM may be prominent with statins only. Statin-induced DM is a much discussed phenomenon. The exact mechanism of statin-induced DM remains unclear, and various mechanisms have been postulated to explain this association. First, statins may derange the glucose metabolism by negative effects on both b-cell secretion and insulin sensitivity. For example, the METSIM (Metabolic Syndrome in Men) study (9749 patients) showed 46% increased relative risk of type 2 DM, 24% reduction in insulin sensitivity, and 12% reduction in insulin secretion in patients taking statins. 59 It is
proposed that b-cell dysfunction might be related to LDLRmediated increased levels of intracellular cholesterol. Studies with murine experimental models have shown that the addition of LDL-C to culture medium of rat islet b cells resulted in cell death. 60, 61 To further explore this concept, Besseling et al conducted a study in patients with familial hypercholesteremia (63 320 patients) and showed that prevalence of type 2 DM was significantly lower in familial hypercholesteremia patients than unaffected relatives (1.75% versus 2.93%, P<0.001).
62
Hypercholesteremia in familial hypercholesteremia is caused by genetically impaired LDLR-mediated transcellular cholesterol transport, whereas, conversely, HMGCR inhibition by statins promotes transmembranous cholesterol uptake by increasing expression of LDLR; therefore, the authors proposed that there might be a causal relationship between LDLRmediated increased internalization of cholesterol into pancreatic b cells and impaired insulin secretion. 62 Second, animal studies have suggested that statin-induced myopathy occurs because of development of muscle insulin resistance 63 ; using this evidence, Preiss et al hypothesized that the risk might be related to the effect of statins on insulin sensitivity in muscle and liver. 7 Third, weight gain may play a causal role in development of DM by increasing insulin resistance. Swerdlow et al studied single-nucleotide polymorphism in HMGCR genes and used rs17238484 and rs12916 as proxies for HMGCR inhibition by statins. 57 This meta-analysis of 43 genetic studies (223 463 patients) showed that these HMGCR single-nucleotide polymorphisms were associated with higher body weight, waist circumference, lower LDL-C, and increased plasma glucose concentration. Finally, genetic data have shown a potential association between LDL-C lowering and incident DM. Lotta et al demonstrated that LDL-C-lowering alleles in or near HMGCR were associated with higher risk of type 2 DM (odds ratio: 1.39; P=0.03).
11 Although the possibility of other mechanisms cannot be excluded, the pooled analyses of randomized controlled trials could not strongly demonstrate an association between lowering LDL-C and incident DM. Lotta and colleagues reported that genetic variants in PCSK9 were associated with a 19% (95% CI, 2-38%) higher RR for DM per 1-mmol/L reduction in LDL-C. 11 On the same note, PCSK9 inhibitor trials also hinted at a potential association of PCSK9 inhibitors with new-onset DM. In FOURIER, the risk of incident DM was numerically higher with PCSK9 inhibitors (hazard ratio: 1.05; P=0.34). 9 However, in a prespecified analysis of the FOURIER trial, evolocumab did not increase the risk of new-onset DM in nondiabetic patients (hazard ratio: 1.05; 95% CI, 0.94-1.17) or those with prediabetes (hazard ratio: 1.00; 95% CI, 0.89-1.13). 65 Similarly, the ODYSSEY OUTCOME trial showed fewer participants with incident DM with PCSK9 inhibitor use compared with placebo. 10 We critically compared our results with prior metaanalyses. Sattar and colleagues showed significantly higher risk of incident DM with statins, but metaregression analysis did not demonstrate an association between change in LDL-C and risk of incident DM. 8 Meta-analysis by Preiss et al (5 statin trials, 32 752 patients) showed 12% relative risk of incident DM with intensive-dose statin therapy compared with moderate-dose statin therapy. 7 De Carvalho et al metaanalyzed 20 randomized controlled trials (68 123 patients) of PCSK9 therapy to investigate its association with incident type 2 DM. 66 They reported that during a median follow-up of 78 weeks, PCSK9 inhibitors increased fasting blood glucose by 1.88 mg/dL and HbA1c by 0.032%; however, this effect did not translate into increased incidence of DM (RR: 1.04; P=0.42). In a metaregression analysis, they showed a 3.8% increase in DM for each 10% lowering of LDL-C levels;
however, this study included the SPIRE trial, which does not reflect contemporary PCSK9 inhibitor therapy. Conversely, findings of Cao et al were consistent with our outcomes. 64 Both studies were published before ODYSSEY OUTCOMES and thus lacked this large data set. 10 To our knowledge, our current study is the largest updated meta-analysis that, in addition to systematically evaluating the association of LDL-C reduction with incident DM, has quantitatively compared the effects of statins and PCSK9 inhibitors to provide a more comprehensive overview of this issue. The current study is subject to limitations. First, this study is a trial-level meta-analysis, and given lack of access to the individual patient data, we could not adjust our analysis for various comorbidities and baseline characteristics such as age, body mass index, baseline fasting blood glucose level, or HbA1c. Therefore, a patient-level meta-analysis could provide more valuable information to further evaluate such associations. Second, PCSK9 inhibitors were conducted in the background of statins. Third, it is important to note that the definition of incident DM was not uniform across the trials. Specifically, most trials reported nonadjudicated outcomes of incident DM; however, we tried to compensate for this by performing sensitivity analyses. Fourth, we could not detect publication bias; that said, because of exclusion of a notable number of trials that did not report incident Figure 7 . Sensitivity analysis, forest plot comparing risk of incident diabetes mellitus among interventions in trials with sample sizes ≥500 patients and follow-up ≥1 year. PCSK9 indicates proprotein convertase subtilisin/kexin type 9.
DM, a certain degree of publication bias could not be completely excluded. Finally, like any meta-analysis, this report is limited by heterogeneity in baseline characteristics, sample sizes, drugs, and durations of studies. Nevertheless, the results had low statistical heterogeneity, and we tried to compensate for variability in sample size and follow-up duration through sensitivity analysis.
In conclusion, the current study does not demonstrate an association between degree of LDL-C lowering by contemporary lipid-lowering therapies and risk of incident DM. Among intense lipid-lowering therapies, the risk of DM was higher with statins only, whereas PCSK9 inhibitors (in setting of background statin therapy) did not show a significant association with incident DM.
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